The US Food and Drug Administration (FDA) recently highlighted three case studies showing how sponsors can incorporate innovative study designs in their clinical trials using the agency’s Complex ...
As biomarker studies employ increasingly complex and expensive genomics and other correlative methods, it is increasingly important to rigorously design these studies and analyze the downstream ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results